Our results showed that EGCG treatment improved the memory and learning impairment in APP/PS1 mice in PAT and MWM tests (Figs. 1, 2, and 3), decreased the expressional levels of APP and Aβ(1–40) (Figs. 5 and 6) and also alleviated the neuronal apoptosis and neurodegeneration (Figs. 7, 8, and 9), indicating that EGCG treatment ameliorated the cognitive deficits in APP/PS1 transgenic mice. Here, APP is linked to Cognitive impairment.